AQST vs. CVAC, CALT, GPCR, AUPH, NAGE, AMPH, DYN, PAHC, BGM, and ABCL
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), BGM Group (BGM), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Aquestive Therapeutics vs. Its Competitors
Aquestive Therapeutics (NASDAQ:AQST) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.
Aquestive Therapeutics presently has a consensus price target of $10.14, suggesting a potential upside of 172.66%. CureVac has a consensus price target of $6.83, suggesting a potential upside of 26.66%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than CureVac.
CureVac has a net margin of 35.44% compared to Aquestive Therapeutics' net margin of -100.02%. CureVac's return on equity of 30.89% beat Aquestive Therapeutics' return on equity.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 8.4% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Aquestive Therapeutics had 3 more articles in the media than CureVac. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 1 mentions for CureVac. Aquestive Therapeutics' average media sentiment score of 0.50 beat CureVac's score of -0.17 indicating that Aquestive Therapeutics is being referred to more favorably in the media.
Aquestive Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.
CureVac has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Summary
Aquestive Therapeutics and CureVac tied by winning 8 of the 16 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:AQST) was last updated on 7/5/2025 by MarketBeat.com Staff
Free AQST Stock Alerts